Expert Review of Cardiovascular Therapy最新文献_第2页

Cost-effectiveness of apixaban in non-valvular atrial fibrillation (NVAF) based on effectiveness data from a Spanish study in clinical practice (real-world evidence). 阿哌沙班治疗非瓣膜性心房颤动（NVAF）的成本-效果：基于西班牙临床实践研究的有效性数据（真实世界证据）。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-01-01 Epub Date: 2025-02-17 DOI: 10.1080/14779072.2025.2464180

Manuel Anguita, Francisco Marín, Javier Soto, Susana Fernández de Cabo, Darío Rubio-Rodríguez, Carlos Rubio-Terrés

{"title":"Cost-effectiveness of apixaban in non-valvular atrial fibrillation (NVAF) based on effectiveness data from a Spanish study in clinical practice (real-world evidence).","authors":"Manuel Anguita, Francisco Marín, Javier Soto, Susana Fernández de Cabo, Darío Rubio-Rodríguez, Carlos Rubio-Terrés","doi":"10.1080/14779072.2025.2464180","DOIUrl":"10.1080/14779072.2025.2464180","url":null,"abstract":"Objective: To analyze the cost-effectiveness of apixaban in the prevention of stroke in adult patients with non-valvular atrial fibrillation (NVAF), compared to other direct-acting oral anticoagulants (dabigatran, rivaroxaban, edoxaban) and the vitamin K antagonist acenocoumarol, based on data on effectiveness in clinical practice in Spain obtained in the FANTASIIA study.Research design and methods: A probabilistic Markov economic model (second-order Monte Carlo simulation) was performed to analyze the costs and utilities (quality-adjusted life years, QALYs) associated with the compared treatments, according to the different probabilities of stroke, major bleeding and death observed in FANTASIIA.Results: The cost per QALY gained in the patient treated with apixaban versus comparators ranged from €2,919 to €7,462. The probability of apixaban being cost-effective ranges from 91.1% (vs dabigatran 150 mg), 97.8% (vs dabigatran 110 mg), and 100% (vs. rivaroxaban, edoxaban, and acenocoumarol).Conclusions: Based on the results of the FANTASIIA study, apixaban is a cost-effective treatment (below a willingness to pay of €25,000 per QALY gained) compared to dabigatran, rivaroxaban, edoxaban, and acenocoumarol in treating patients with NVAF.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"45-51"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What role could clinical staging standardization play in Fabry disease? 临床分期标准化对法布里病有何作用？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-01-01 Epub Date: 2025-03-05 DOI: 10.1080/14779072.2025.2476128

Elisabete Martins, Janete Santos, Inês Fortuna

引用次数: 0

The fitter the better? The relationship between high cardiorespiratory fitness and the risk of atrial fibrillation and stroke. 越健康越好？高心肺适能与房颤和中风风险的关系。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-01-01 Epub Date: 2025-03-06 DOI: 10.1080/14779072.2025.2476123

Marius Myrstad, Adrian Elliott

引用次数: 0

Risk scoring systems for early prediction of short-term mortality in resuscitated out-of-hospital cardiac arrest patients. 院外心脏骤停复苏患者短期死亡率早期预测的风险评分系统。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-01-01 Epub Date: 2025-01-04 DOI: 10.1080/14779072.2025.2449899

Tharusan Thevathasan, Ulf Landmesser, Anne Freund, Janine Pöss, Carsten Skurk, Holger Thiele, Steffen Desch

{"title":"Risk scoring systems for early prediction of short-term mortality in resuscitated out-of-hospital cardiac arrest patients.","authors":"Tharusan Thevathasan, Ulf Landmesser, Anne Freund, Janine Pöss, Carsten Skurk, Holger Thiele, Steffen Desch","doi":"10.1080/14779072.2025.2449899","DOIUrl":"10.1080/14779072.2025.2449899","url":null,"abstract":"Introduction: Out-of-hospital cardiac arrest (OHCA) is a critical condition associated with high mortality rates and neurological impairment among survivors. In comatose OHCA patients who achieve return of spontaneous circulation, early risk stratification is important to inform treatment pathways and potentially improve outcomes. A range of prognostic tools have been developed to predict survival and neurological recovery. Each tool incorporates a unique combination of clinical, biochemical and physiological markers.Areas covered: This review article evaluates the required clinical data, predictive performances and practical applicability of major risk scores. A literature review was conducted in PubMed and Embase for studies published between January 2000 and October 2024. The review emphasizes the variability in discriminative power among the selected scores, with some models offering high sensitivity and specificity in outcome prediction, while others prioritize simplicity and accessibility.Expert opinion: Despite the advancements of these tools, limitations persist in data dependency and the clinical adaptability, highlighting areas for future improvement. Integrating artificial intelligence and real-time analytics could enhance predictive accuracy, offering dynamic prognostic capabilities that adapt to individual patient trajectories. This evolution must be grounded in ethical considerations to ensure predictive technologies complement rather than replace clinical judgment, balancing technology's potential with the complexities of individualized patient care.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"5-13"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is transthyretin amyloid cardiomyopathy heading towards losing its rare disease classification? 转甲状腺蛋白淀粉样心肌病正在失去其罕见疾病分类吗？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-01-01 Epub Date: 2025-02-10 DOI: 10.1080/14779072.2025.2463333

Anouk Achten, Steven A Muller, Peter-Paul Zwetsloot, Michelle Michels, Peter van der Meer, Hans L A Nienhuis, Manon G van der Meer, Vanessa P M van Empel, Marish I F J Oerlemans, Christian Knackstedt

引用次数: 0

The gut microbiota and its role in the development of cardiovascular disease. 肠道微生物群及其在心血管疾病发展中的作用。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-01-01 Epub Date: 2025-02-10 DOI: 10.1080/14779072.2025.2463366

Carlos Escobar, Xavier Aldeguer, David Vivas, Sergio Manzano Fernández, Eva Gonzalez Caballero, Ana Garcia Martín, Vivencio Barrios, Román Freixa-Pamias

{"title":"The gut microbiota and its role in the development of cardiovascular disease.","authors":"Carlos Escobar, Xavier Aldeguer, David Vivas, Sergio Manzano Fernández, Eva Gonzalez Caballero, Ana Garcia Martín, Vivencio Barrios, Román Freixa-Pamias","doi":"10.1080/14779072.2025.2463366","DOIUrl":"10.1080/14779072.2025.2463366","url":null,"abstract":"Introduction: The pathophysiology of cardiovascular diseases encompasses a complex interplay of genetic and environmental risk factors. Even if traditional risk factors are treated to target, there remains a residual risk.Areas covered: This manuscript reviews the potential role of gut microbiota in the development of cardiovascular disease, and as potential target. A systematic search was conducted until 30 October 2024 on PubMed (MEDLINE), using the MeSH terms [Gut microbiota] + [Dysbiosis] + [Cardiovascular] + [TMAO] + [bile acids] + [short-chain fatty acids].Expert opinion: The term dysbiosis implies changes in equilibrium, with modifications in the composition and functionality of microbiota and a series of additional factors: reduced diversity and uniformity of microorganisms; reduced short-chain fatty acid-producing bacteria; increased gut permeability; release of metabolites, such as trimethylamine N-oxide, betaine, phenylalanine, tryptophan-kynurenine, phenylacetylglutamine, and lipopolysaccharides; and reduced secondary bile acid excretion, leading to inflammation, oxidative stress, and endothelial dysfunction and facilitating the onset of pathological conditions, including obesity, hypertension, diabetes, atherosclerosis, and heart failure. Attempts to restore gut microbiota balance through different interventions, mainly changes in diet, have been shown to positively affect individual components and metabolites and reduce the risk of cardiovascular disease. In addition, probiotics and prebiotics are potentially useful. Fecal microbiota transplantation is a promising therapy.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"23-34"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolocumab for the reduction of cardiovascular risk in HIV patients: is this a clinician's best option for HIV patients? Evolocumab用于降低HIV患者心血管风险：这是临床医生对HIV患者的最佳选择吗？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-01-01 Epub Date: 2025-02-07 DOI: 10.1080/14779072.2025.2463348

Francisco Akira Malta Cardozo, Luciana Dornfeld Bichuette, Bruno Caramelli

{"title":"Evolocumab for the reduction of cardiovascular risk in HIV patients: is this a clinician's best option for HIV patients?","authors":"Francisco Akira Malta Cardozo, Luciana Dornfeld Bichuette, Bruno Caramelli","doi":"10.1080/14779072.2025.2463348","DOIUrl":"10.1080/14779072.2025.2463348","url":null,"abstract":"Introduction: People living with HIV (PLHIV) are at higher risk of cardiovascular disease (CVD), and dyslipidemia is a prevalent comorbidity that requires effective treatment. Limitations for the use of statins such as drug interactions and adverse effects highlight the need for alternative therapies.Areas covered: This review evaluates the role of PCSK9 inhibitors in reducing cardiovascular risk in PLHIV with dyslipidemia. We analyzed studies available on PUBMED, using keywords HIV, dyslipidemia, PCSK9 inhibitors, and statin intolerance. We discuss the mechanisms underlying increased cardiovascular risk, limitations of statins, including a recent study using PCSK9 inhibitors. Evolocumab significantly reduced LDL-C levels by 56.9% in PLHIV, with 72.5% of patients achieving ≥50% LDL-C reduction. The trial confirmed the drug's safety. Additionally, PCSK9 inhibitors demonstrated reductions in lipoprotein(a) and inflammatory markers.Expert opinion: PCSK9i present a promising option for lipid management in PLHIV, especially in statin-intolerant individuals or those with residual risk despite statin therapy. Additional non-statin therapies targeting adverse lipid profiles, including low HDL-C, high triglycerides, and lipoprotein(a), are under development. Combined with advancements in antisense oligonucleotides (ASOs) and siRNA technologies, they hold promise for transforming the treatment of dyslipidemia and cardiovascular disease in PLHIV.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"15-21"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Surgical pulmonary valve redo versus transcatheter pulmonary valve replacement for Tetralogy of Fallot patients. 法洛氏四联症患者肺动脉瓣重修手术与经导管肺动脉瓣置换术的比较。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-01-01 Epub Date: 2025-03-24 DOI: 10.1080/14779072.2025.2482926

Michail Penteris, Konstantinos Lampropoulos

{"title":"Surgical pulmonary valve redo versus transcatheter pulmonary valve replacement for Tetralogy of Fallot patients.","authors":"Michail Penteris, Konstantinos Lampropoulos","doi":"10.1080/14779072.2025.2482926","DOIUrl":"10.1080/14779072.2025.2482926","url":null,"abstract":"Objectives: To perform a systematic review to compare the efficacy and safety of transcatheter pulmonary valve replacement (TPVR) and surgical pulmonary valve replacement (SPVR) in managing pulmonary valve dysfunction in Tetralogy of Fallot (TOF) patients.Methods: This review investigates through three different databases for randomized control trials or observational studies evaluating TOF patients who underwent TPVR or SPVR until November 2024. The outcomes of interest were hemodynamic improvement, reduction in pulmonary regurgitation or stenosis, complications, quality of life, and long-term outcomes.Results: Four retrospective studies (1919 procedures) were analyzed. TPVR was non-inferior to SPVR, with a comparable safety profile. The durability of bioprosthetic valves was similar between TPVR and SPVR (HR: 0.97, 95% CI: 0.55-1.73; p = 0.93) and was influenced by patients' age at PVR (HR: 0.78 per 10 years from <1 year; 95% CI: 0.63-0.96; p = 0.02) and true inner valve diameter .Conclusions: TPVR is a safe and less-invasive alternative to SPVR with comparable efficacy in reducing pulmonary regurgitation. Complication rates are similar and valve durability is primarily age- and valve size-dependent. Although further research on long term outcomes is needed, TPVR may be integrated into routine practices, offering a viable alternative for high-risk TOF patients.Registration: This systematic review was registered on the international prospective register of systematic reviews (PROSPERO; #CRD42024615871).","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"87-95"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Temporal trends in cardiovascular mortality among patients with hematological malignancies: a 20-year perspective. 恶性血液病患者心血管死亡率的时间趋势：20年的观察

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-01-01 Epub Date: 2025-02-12 DOI: 10.1080/14779072.2025.2463332

Gemina Doolub, Avraham Raichman, Dmitry Abramov, Vijay Bang, Purvi Parwani, Kamaraj Karunanithi, Hussam Abdel-Qadir, Ofer Kobo, Mamas A Mamas

{"title":"Temporal trends in cardiovascular mortality among patients with hematological malignancies: a 20-year perspective.","authors":"Gemina Doolub, Avraham Raichman, Dmitry Abramov, Vijay Bang, Purvi Parwani, Kamaraj Karunanithi, Hussam Abdel-Qadir, Ofer Kobo, Mamas A Mamas","doi":"10.1080/14779072.2025.2463332","DOIUrl":"10.1080/14779072.2025.2463332","url":null,"abstract":"Background: We present an analysis of cardiovascular-related deaths specific to hematological cancer patients in the United States from 1999 to 2020, examining trends in relation to age, gender, and type of hematological cancer.Research design and methods: Utilizing the Multiple Cause of Death databases, our research included 88,146 decedents with cardiovascular primary cause of death and with hematologic disease. We determined the percentage of cardiovascular deaths associated with each disease category. Furthermore, we developed age-adjusted mortality rates, categorizing them based on sex, age, race, Latino origin, and the type of hematological cancer.Results: Between 1999 and 2020, there was a decreasing temporal trend in overall cardiovascular mortality for lymphoma, leukemia and multiple myeloma (-38.8% -31.8% & -29.4%). The most common cardiovascular mortality cause in the hematological malignancy population was ischemic heart disease, followed by cerebrovascular disease (53.4%, 20.2%). African American, Asian, and White patients showed decreasing for overall CV death for all hematological malignancies, with African American subgroups showing the lowest mortality reduction over time (AAMR: -26.8%, -41.2%, -33.3%). However, hypertension mortality increased for most racial groups.Conclusions: Over the last 2 decades, the rate of cardiovascular mortality amongst patients with underlying hematological malignancy has decreased.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"35-43"},"PeriodicalIF":1.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiotoxicity and triazole pesticides: therapeutic options for a neglected heart disease. 心脏毒性和三唑类杀虫剂：一种被忽视的心脏病的治疗选择。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-01-01 Epub Date: 2025-03-09 DOI: 10.1080/14779072.2025.2476124

Diego Santos Souza, Danilo Roman-Campos

引用次数: 0